Ligand Pharmaceuticals Inc.  

(Public, NASDAQ:LGND)   Watch this stock  
Find more results for LGND
89.67
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 41.99 - 90.48
Open     -
Vol / Avg. 0.00/395,354.00
Mkt cap 1.76B
P/E 174.45
Div/yield     -
EPS 0.51
Shares 19.67M
Beta 1.13
Inst. own 114%
Aug 3, 2015
Q2 2015 Ligand Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 12, 2015
Ligand Pharmaceuticals Inc at Bank of America Merrill Lynch Health Care Conference
May 11, 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Release
May 11, 2015
Q1 2015 Ligand Pharmaceuticals Inc Earnings Call
May 6, 2015
Ligand Pharmaceuticals Inc at Deutsche Bank Health Care Conference
Mar 9, 2015
Ligand Pharmaceuticals Inc at ROTH Conference
Feb 24, 2015
Ligand Pharmaceuticals Inc at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -0.61% 16.88%
Operating margin 22.94% 30.41%
EBITD margin - 36.27%
Return on average assets -0.14% 6.01%
Return on average equity 9.84% 31.67%
Employees 19 -
CDP Score - -

Address

Suite 200, 11119 North Torrey Pines Road
LA JOLLA, CA 92037
United States - Map
+1-858-5507500 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Ligand Pharmaceuticals Incorporated is a biotechnology company that operates with a business model focused on developing or acquiring revenue generating assets and coupling them with a lean corporate cost structure. The Company’s technology CAPTISOL is a formulation technology that has enabled six products, including Onyx's Kyprolis and Baxter International's Nexterone, while partnering in several clinical-stage programs. The therapies in the Company’s development portfolio address the unmet medical needs of patients for a broad spectrum of diseases including hepatitis, immune (idiopathic) thrombocytopenic purpura, or ITP, muscle wasting, multiple myeloma, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, Focal Segmental Glomerulosclerosis, or FSGS and osteoporosis. The Company has potential revenue-generating programs, over 90 of which are fully-funded by its partners.

Officers and directors

John W. Kozarich Ph.D. Independent Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Matthew W. Foehr President, Chief Operating Officer
Age: 42
Bio & Compensation  - Reuters
John L. Higgins Chief Executive Officer, Director
Bio & Compensation  - Reuters
Nishan M. de Silva M.D. Chief Financial Officer, Vice President - Finance and Strategy
Age: 41
Bio & Compensation  - Reuters
Charles S. Berkman J.D. Vice President, General Counsel, Secretary
Age: 46
Bio & Compensation  - Reuters
Jason M. Aryeh Independent Director
Age: 46
Bio & Compensation  - Reuters
Todd C. Davis Independent Director
Age: 54
Bio & Compensation  - Reuters
David M. Knott Independent Director
Age: 70
Bio & Compensation  - Reuters
John L. LaMattina Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Sunil Patel Independent Director
Age: 43
Bio & Compensation  - Reuters